Agentes vasoactivos en sepsis: revisión crítica de la literatura

Uno de los objetivos terapéuticos más importantes en el abordaje del paciente séptico es impactar tempranamente en el curso de la vasoplejia subyacente, por medio de medicamentos con potencial vasoactivo. Si bien se plantea un manejo multimodal que incluya técnicas de monitoreo apropiadas y enfoques personalizados, la vasoconstricción excesiva puede empeorar la insuficiencia orgánica múltiple, así como algunos inodilatadores ser deletéreos para el perfil hemodinámico de pacientes con choque séptico. Ofrecemos una revisión actualizada de la evidencia en el uso de vasoactivos en pacientes con sepsis.

[1]  M. Nalos,et al.  Restriction of Intravenous Fluid in ICU Patients with Septic Shock. , 2022, The New England journal of medicine.

[2]  J. Kellum,et al.  Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial. , 2021, JAMA.

[3]  J. Kellum,et al.  Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial. , 2021, JAMA.

[4]  S. Fernando,et al.  Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. , 2021, The New England journal of medicine.

[5]  James F. Gilmore,et al.  Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock* , 2020, Critical care medicine.

[6]  G. Ospina-Tascón,et al.  Inodilators in septic shock: should these be used? , 2020, Annals of translational medicine.

[7]  J. Bakker,et al.  Should we start vasopressors very early in septic shock? , 2020, Journal of thoracic disease.

[8]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[9]  R. Sato,et al.  Effects of Inotropes on the Mortality in Patients With Septic Shock , 2019, Journal of intensive care medicine.

[10]  Shutang Han,et al.  Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials , 2019, Critical Care.

[11]  G. Perkins,et al.  Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials , 2019, Intensive Care Medicine.

[12]  C. Permpikul,et al.  Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial , 2019, American journal of respiratory and critical care medicine.

[13]  A. Gordon,et al.  Early May Be Better: Early Low-Dose Norepinephrine in Septic Shock , 2019, American journal of respiratory and critical care medicine.

[14]  C. Yancy,et al.  Shock – Classification and Pathophysiological Principles of Therapeutics , 2019, Current cardiology reviews.

[15]  K. Walley,et al.  Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital , 2018, Journal of Intensive Care.

[16]  Bethany R. Shoulders,et al.  Recent Updates in the Pharmacological Management of Sepsis and Septic Shock: A Systematic Review Focused on Fluid Resuscitation, Vasopressors, and Corticosteroids , 2018, The Annals of pharmacotherapy.

[17]  D. Wyncoll,et al.  Refractory septic shock: our pragmatic approach , 2018, Critical Care.

[18]  Kristen A. Severson,et al.  Vasopressin Administration Is Associated With Rising Serum Lactate Levels in Patients With Sepsis , 2018, Journal of intensive care medicine.

[19]  D. Sessler,et al.  The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients , 2018, Intensive Care Medicine.

[20]  J. Healey,et al.  Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis , 2018, JAMA.

[21]  J. Painter,et al.  Prospective Open‐label Trial of Early Concomitant Vasopressin and Norepinephrine Therapy versus Initial Norepinephrine Monotherapy in Septic Shock , 2018, Pharmacotherapy.

[22]  Mitchell M. Levy,et al.  The Surviving Sepsis Campaign Bundle: 2018 update , 2018, Intensive Care Medicine.

[23]  D. Aschenbrenner.  New Hypotension Treatment for Septic Shock. , 2018, The American journal of nursing.

[24]  Jian-feng Xie,et al.  Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials , 2018, BMJ Open.

[25]  G. Beilman,et al.  Vasopressors in Sepsis. , 2018, Surgical infections.

[26]  M. Jozwiak,et al.  Norepinephrine exerts an inotropic effect during the early phase of human septic shock , 2017, British journal of anaesthesia.

[27]  M. Pinsky,et al.  Norepinephrine improves cardiac function during septic shock, but why? , 2017, British journal of anaesthesia.

[28]  R. Sato,et al.  Time to re-think the use of dobutamine in sepsis , 2017, Journal of Intensive Care.

[29]  K. Soni,et al.  Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials. , 2017, Journal of clinical anesthesia.

[30]  R. Bellomo,et al.  Angiotensin II for the Treatment of Vasodilatory Shock , 2017, The New England journal of medicine.

[31]  T. Osborn.  Severe Sepsis and Septic Shock Trials (ProCESS, ARISE, ProMISe): What is Optimal Resuscitation? , 2017, Critical care clinics.

[32]  J. Arbo,et al.  Vasopressors and Inotropes in Sepsis. , 2017, Emergency medicine clinics of North America.

[33]  G. Angelini,et al.  The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta‐analysis of randomized trials , 2017, Journal of critical care.

[34]  S. Magder.  Erratum to: Volume and its relationship to cardiac output and venous return , 2017, Critical Care.

[35]  S. Magder.  Volume and its relationship to cardiac output and venous return , 2016, Critical Care.

[36]  G. Perkins,et al.  Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. , 2016, JAMA.

[37]  Takashi Ito,et al.  Sepsis-induced myocardial dysfunction: pathophysiology and management , 2016, Journal of Intensive Care.

[38]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[39]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[40]  T. Rea,et al.  Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[41]  J. D. Young,et al.  Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock. , 2015, Health technology assessment.

[42]  A. Zangrillo,et al.  Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. , 2015, Journal of critical care.

[43]  Leonard Leibovici,et al.  Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis , 2015, PloS one.

[44]  A. Zangrillo,et al.  A Bayesian network meta-analysis on the effect of inodilatory agents on mortality. , 2015, British journal of anaesthesia.

[45]  M. Schmidhofer,et al.  Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit , 2015, Journal of cardiovascular pharmacology and therapeutics.

[46]  V. Tómicic,et al.  Milrinone role in treatment of septic shock , 2015, Critical Care.

[47]  Wu Ji,et al.  Early versus delayed administration of norepinephrine in patients with septic shock , 2014, Critical Care.

[48]  Amber E Barnato,et al.  A randomized trial of protocol-based care for early septic shock. , 2014, The New England journal of medicine.

[49]  G. Ramachandran.  Gram-positive and gram-negative bacterial toxins in sepsis , 2013, Virulence.

[50]  A. Serpa Neto,et al.  Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials , 2012, Critical Care.

[51]  K. Mahmoud,et al.  Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock , 2012, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[52]  J. Vincent,et al.  Dopamine versus norepinephrine in the treatment of septic shock: A meta-analysis* , 2012, Critical care medicine.

[53]  C. Richard,et al.  Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotension , 2010, Critical care.

[54]  J. Vincent,et al.  Comparison of dopamine and norepinephrine in the treatment of shock. , 2010, The New England journal of medicine.

[55]  Daryl A Jones,et al.  Australasian resuscitation of sepsis evaluation (ARISE): A multi-centre, prospective, inception cohort study. , 2009, Resuscitation.

[56]  D. Cook,et al.  Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock* , 2009, Critical care medicine.

[57]  Stephan M. Jakob,et al.  Arterial blood pressure during early sepsis and outcome , 2009, Intensive Care Medicine.

[58]  M. Westphal,et al.  Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial , 2008, Critical care.

[59]  V. Džavík,et al.  Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease , 2008, Circulation.

[60]  Therapy Study Investigators,et al.  A comparison of epinephrine and norepinephrine in critically ill patients , 2008, Intensive Care Medicine.

[61]  Sangeeta Mehta,et al.  Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.

[62]  D. Annane,et al.  Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial , 2007, The Lancet.

[63]  L. Lehtonen,et al.  The utility of levosimendan in the treatment of heart failure , 2007, Annals of medicine.

[64]  M. Gheorghiade,et al.  Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. , 2005, The American journal of cardiology.

[65]  V. Pettilä,et al.  Hemodynamic variables related to outcome in septic shock , 2005, Intensive Care Medicine.

[66]  F. F. Yoong,et al.  Vasopressin and terlipressin: pharmacology and its clinical relevance , 2004, Anaesthesia.

[67]  R. Bellomo,et al.  Early and exclusive use of norepinephrine in septic shock. , 2004, Resuscitation.

[68]  B. Yard,et al.  Clinical review: Immunomodulatory effects of dopamine in general inflammation , 2004, Critical care.

[69]  P. Marik.  Low-dose dopamine: a systematic review , 2002, Intensive Care Medicine.

[70]  D. Chittock,et al.  Beneficial Effects of Short-term Vasopressin Infusion during Severe Septic Shock , 2002, Anesthesiology.

[71]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[72]  J. Kellum,et al.  Use of dopamine in acute renal failure: A meta-analysis , 2001, Critical care medicine.

[73]  M. Oz,et al.  Vasopressin deficiency contributes to the vasodilation of septic shock. , 1997, Circulation.

[74]  P. Barnes,et al.  Long-term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary beta-adrenergic receptors in guinea pigs. , 1994, American journal of respiratory cell and molecular biology.